Tyra Bioscience Prices $400 Million Offering of Shares and Warrants

07:01 AM EDT, 09/14/2026 (MT Newswires) -- Tyra Bioscience (TYRA) said Monday it has priced its $400 million underwritten offering of 9.1 million common shares and pre-funded warrants each at $22.03 apiece. The company said it intends to use net proceeds from the offering, along with existing cash, for its low-grade upper tract urothelial carcinoma, intermediate-risk non-muscle invasive bladder cancer, and achondroplasia programs, and other general corporate purposes. Tyra said RA Capital Management led the offering, with participation from Invus, Commodore Capital, BVF Partners, Janus Henderson Investors, and other investment management firms. The offering is expected to close on Tuesday, the company said. Shares of the company were up 1.5% in Monday's premarket activity.